(2023)
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.
Blood Res.
58,
4
(2023)
The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma.
FRONTIERS IN ONCOLOGY.
13,
(2023)
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation.
FRONTIERS IN ONCOLOGY.
13,
(2023)
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study.
BLOOD CANCER JOURNAL.
13,
1
(2023)
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
NEW ENGLAND JOURNAL OF MEDICINE.
389,
4
(2023)
Clinical relevance of deep learning models in predicting the onset timing of cancer pain exacerbation.
SCIENTIFIC REPORTS.
13,
1
(2023)
Direct comparison of diagnostic and clinical values between Tc-99 m DPD and Tc-99 m PYP scintigraphy in patients with cardiac amyloidosis.
BMC MEDICAL IMAGING.
23,
1
(2023)
Retrospective analysis of diagnosis and therapeutic strategies for patients with hepatosplenic T cell lymphoma.
ANNALS OF HEMATOLOGY.
102,
7
(2023)
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation.
BLOOD CANCER JOURNAL.
13,
1
(2023)
Metabolic bulk volume predicts survival in a homogeneous cohort of stage II/III diffuse large B-cell lymphoma patients undergoing R-CHOP treatment.
FRONTIERS IN ONCOLOGY.
13,
(2023)
Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma.
CANCER MANAGEMENT AND RESEARCH.
15,
(2023)
TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
CANCER.
129,
10
(2023)
The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma.
BLOOD.
141,
18
(2023)
Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections.
FRONTIERS IN IMMUNOLOGY.
14,
(2023)
Comparison of histological and molecular features of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma (Jan, 10.1007/s00428-023-03493-x, 2023).
VIRCHOWS ARCHIV.
482,
5
(2023)
Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).
CANCER RESEARCH AND TREATMENT.
55,
2
(2023)
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
CANCER RESEARCH AND TREATMENT.
55,
3
(2023)
In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas.
FRONTIERS IN ONCOLOGY.
13,
(2023)
Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA.
23,
2
(2023)
Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma.
FRONTIERS IN ONCOLOGY.
12,
학술회의논문
(2009)
Treatment Outcome of Steroid-Refractory Chronic Graft-Versus-Host Disease with Weekly Rituximab Followed by Maintenance Rituximab: a KSBMT Multicenter Phase II Study.
The 51st annual meeting American society of hematology.
미국
(2009)
COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH INTESTINAL NON-HODGKIN LYMPHOMA: CHEMOTHERAPY VERSUS SURGERY FOLLOWED BY CHEMOTHERAPY.
2009 ISOQOL meeting.
미국
(2009)
Revised international prognostic index in diffuse large B-cell lymphoma of small and large intestine.
The 71st Annual meeting of the Japanese Society of Hematology.
일본
(2009)
Immunoglobulin D multiple myeloma: Clinical presentation, response to therapy and prognostic factors in 77 patients.
제50차 대한혈액학회 춘계학술대회.
대한민국
(2009)
Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma.
제50차 대한혈액학회 춘계학술대회.
대한민국
(2009)
Primary mediastinal large B-cell lymphoma: A single center experience.
제50차 대한혈액학회 춘계학술대회.
대한민국
(2009)
Prognosis and qulaity of life in non-Hodgkin lymphoma of intestine: Multicenter analysis.
제50차 대한혈액학회 춘계학술대회.
대한민국
(2009)
The effect of bortezomib on bone metabolism of patients with multiple myeloma: a multicenter prospective study.
제50차 대한혈액학회 춘계학술대회.
대한민국
(2009)
Non-Hodgkin lymphoma of rare extranodal sites: Are they different from commonly involved sites?.
제50차 대한혈액학회 춘계학술대회.
대한민국
(2009)
Pulmonary marginal zone B-cell lymphoma of MALT type: Clinical manifestation and treatment outcomes.
제50차 대한혈액학회 춘계학술대회.
대한민국
(2009)
Multicenter phase II study of rituximab in patients with steroid-refractory chronic graft-versus-host disease: Results of interim analysis.
제13차 대한조혈모세포이식학회 동계학술대회.
대한민국
